These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 24155314)

  • 1. Dopamine-dependent compensation maintains motor behavior in mice with developmental ablation of dopaminergic neurons.
    Golden JP; Demaro JA; Knoten A; Hoshi M; Pehek E; Johnson EM; Gereau RW; Jain S
    J Neurosci; 2013 Oct; 33(43):17095-107. PubMed ID: 24155314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ghrelin on the motor deficit caused by the ablation of nigrostriatal dopaminergic cells or the inhibition of striatal dopamine receptors.
    Suda Y; Kuzumaki N; Narita M; Hamada Y; Shibasaki M; Tanaka K; Tamura H; Kawamura T; Kondo T; Yamanaka A; Narita M
    Biochem Biophys Res Commun; 2018 Feb; 496(4):1102-1108. PubMed ID: 29378186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attenuated dopaminergic neurodegeneration and motor dysfunction in hemiparkinsonian mice lacking the α5 nicotinic acetylcholine receptor subunit.
    Leino S; Koski SK; Hänninen R; Tapanainen T; Rannanpää S; Salminen O
    Neuropharmacology; 2018 Aug; 138():371-380. PubMed ID: 29940207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RGS Proteins as Critical Regulators of Motor Function and Their Implications in Parkinson's Disease.
    Ahlers-Dannen KE; Spicer MM; Fisher RA
    Mol Pharmacol; 2020 Dec; 98(6):730-738. PubMed ID: 32015009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits.
    Masoud ST; Vecchio LM; Bergeron Y; Hossain MM; Nguyen LT; Bermejo MK; Kile B; Sotnikova TD; Siesser WB; Gainetdinov RR; Wightman RM; Caron MG; Richardson JR; Miller GW; Ramsey AJ; Cyr M; Salahpour A
    Neurobiol Dis; 2015 Feb; 74():66-75. PubMed ID: 25447236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic reduction of mitochondrial complex I function does not lead to loss of dopamine neurons in vivo.
    Kim HW; Choi WS; Sorscher N; Park HJ; Tronche F; Palmiter RD; Xia Z
    Neurobiol Aging; 2015 Sep; 36(9):2617-27. PubMed ID: 26070241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pioglitazone ameliorates the phenotype of a novel Parkinson's disease mouse model by reducing neuroinflammation.
    Pinto M; Nissanka N; Peralta S; Brambilla R; Diaz F; Moraes CT
    Mol Neurodegener; 2016 Apr; 11():25. PubMed ID: 27038906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative contributions of severe dopaminergic neuron ablation and dopamine depletion to cognitive impairment.
    Morgan RG; Gibbs JT; Melief EJ; Postupna NO; Sherfield EE; Wilson A; Keene CD; Montine TJ; Palmiter RD; Darvas M
    Exp Neurol; 2015 Sep; 271():205-14. PubMed ID: 26079646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperactive Response of Direct Pathway Striatal Projection Neurons to L-dopa and D1 Agonism in Freely Moving Parkinsonian Mice.
    Sagot B; Li L; Zhou FM
    Front Neural Circuits; 2018; 12():57. PubMed ID: 30104963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. H2O2- or l-DOPA-injured dopaminergic neurons trigger the release of soluble mediators that up-regulate striatal GDNF through different signalling pathways.
    Fonseca CP; Gama S; Saavedra A; Baltazar G
    Biochim Biophys Acta; 2014 Jul; 1842(7):927-34. PubMed ID: 24632468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanding the repertoire of L-DOPA's actions: A comprehensive review of its functional neurochemistry.
    De Deurwaerdère P; Di Giovanni G; Millan MJ
    Prog Neurobiol; 2017 Apr; 151():57-100. PubMed ID: 27389773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preserved striatal innervation maintains motor function despite severe loss of nigral dopaminergic neurons.
    Paß T; Ricke KM; Hofmann P; Chowdhury RS; Nie Y; Chinnery P; Endepols H; Neumaier B; Carvalho A; Rigoux L; Steculorum SM; Prudent J; Riemer T; Aswendt M; Liss B; Brachvogel B; Wiesner RJ
    Brain; 2024 Sep; 147(9):3189-3203. PubMed ID: 38574200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subchronic polychlorinated biphenyl (Aroclor 1254) exposure produces oxidative damage and neuronal death of ventral midbrain dopaminergic systems.
    Lee DW; Notter SA; Thiruchelvam M; Dever DP; Fitzpatrick R; Kostyniak PJ; Cory-Slechta DA; Opanashuk LA
    Toxicol Sci; 2012 Feb; 125(2):496-508. PubMed ID: 22094459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
    Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
    Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence that L-dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms.
    Robertson GS; Robertson HA
    J Neurosci; 1989 Sep; 9(9):3326-31. PubMed ID: 2795165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual effects of L-DOPA on nigral dopaminergic neurons.
    Guatteo E; Yee A; McKearney J; Cucchiaroni ML; Armogida M; Berretta N; Mercuri NB; Lipski J
    Exp Neurol; 2013 Sep; 247():582-94. PubMed ID: 23481547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The transfection of BDNF to dopamine neurons potentiates the effect of dopamine D3 receptor agonist recovering the striatal innervation, dendritic spines and motor behavior in an aged rat model of Parkinson's disease.
    Razgado-Hernandez LF; Espadas-Alvarez AJ; Reyna-Velazquez P; Sierra-Sanchez A; Anaya-Martinez V; Jimenez-Estrada I; Bannon MJ; Martinez-Fong D; Aceves-Ruiz J
    PLoS One; 2015; 10(2):e0117391. PubMed ID: 25693197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chondroitinase ABC reduces dopaminergic nigral cell death and striatal terminal loss in a 6-hydroxydopamine partial lesion mouse model of Parkinson's disease.
    Fletcher EJR; Moon LDF; Duty S
    BMC Neurosci; 2019 Dec; 20(1):61. PubMed ID: 31862005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methamphetamine causes degeneration of dopamine cell bodies and terminals of the nigrostriatal pathway evidenced by silver staining.
    Ares-Santos S; Granado N; Espadas I; Martinez-Murillo R; Moratalla R
    Neuropsychopharmacology; 2014 Apr; 39(5):1066-80. PubMed ID: 24169803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.